Morningside Ventures
Signal active
Investment Firm
Overview
Morningside Ventures is an investment firm
Highlights
Founded
Invalid date
Industry
Financial Services
Employees
11-50
Investment
23
Lead Investment
9
Exits
1
Stages
Early Stage Venture, Seed, Late Stage Venture, Private Equity
Investor Type
Venture Capital
Location
Asia
Contact Information
Social
N/A
Profile Resume
Morningside Ventures, established in Unknown year and headquartered in Asia., specializes in Early Stage Venture, Seed, Late Stage Venture, Private Equity investments across Biotechnology, Life Science, Oncology, Financial Services, Venture Capital, Angel Investment, Asset Management, Health Care, Non Profit, Construction. The organization boasts a portfolio of 23 investments, with an average round size of $61.0M and 1 successful exits. Their recent investments include TransThera Biosciences, Grand Yangtze Capital, Founders' Co-op, Memorial Hermann Foundation, Star Equity Holdings. The highest investment round they participated in was $108.5B. Among their most notable exits are TransThera Biosciences and Grand Yangtze Capital. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Employees
N/A
Investment portfolio
Morningside Ventures has made 23 investments. Their most recent investment was on May 17, 2023, when Cyted raised $16.7M.
Morningside Ventures has made 3 diversity investments. Their most recent diversity investment was on May 10, 2022, when SimpliFed raised $6.0M.
investments
23
Diversity investments
3
Lead investments
9
Number of exits
1
Investments
23
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Nov 23, 2022 | New Amsterdam Pharma | Biotechnology | 235.0M |
| Dec 05, 2022 | Wangli Technology | Health Care | 14.4M |
| May 17, 2023 | Cyted | Biotechnology | 16.7M |
| Sep 11, 2023 | - | - | 10.0M |
Exits
1
Funding Timeline
Funding rounds
23
Investors
0
Funds
0
Funding Rounds
23
Morningside Ventures has raised 23 rounds. Their latest funding was raised on Sep 11, 2023 from a Series B - AdaptX round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Nov 23, 2022 | Post-IPO Equity - New Amsterdam Pharma | - | 235.0M | - |
| Dec 05, 2022 | Venture Round - Wangli Technology | - | 14.4M | - |
| May 17, 2023 | Series A - Cyted | - | 16.7M | - |
| Sep 11, 2023 | Series B - AdaptX | - | 10.0M | - |
Investors
0
There is no funding round available on this profile
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.